Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?

Yim SY, Seo YS, Jung CH, Kim TH, Lee JM, Kim ES, Keum B, Jong YK, An H, Kim JH, Yim HJ, Kim DS, Jeen YT, Yeon JE, Lee HS, Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS.

Liver Int. 2016 Mar;36(3):445-53. doi: 10.1111/liv.12960. Epub 2015 Oct 12.

PMID:
26352789
2.

Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M, Terracciano F, Ginanni B, Sacco R.

Dig Dis Sci. 2015 May;60(5):1465-73. doi: 10.1007/s10620-014-3427-5. Epub 2014 Nov 16.

PMID:
25399329
3.

Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening.

Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF, Tsai LS, Lu SN.

J Gastroenterol Hepatol. 2010 Aug;25(8):1426-34. doi: 10.1111/j.1440-1746.2010.06285.x.

PMID:
20659234
4.

A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy.

Gray SH, White JA, Li P, Kilgore ML, Redden DT, Abdel Aal AK, Simpson HN, McGuire B, Eckhoff DE, Dubay DA.

J Vasc Interv Radiol. 2017 Feb;28(2):231-237.e2. doi: 10.1016/j.jvir.2016.09.022. Epub 2016 Dec 9.

5.

Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm.

Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, von Tengg-Kobligk H, Candinas D, Dufour JF.

Ann Hepatol. 2016 Jan-Feb;15(1):82-90.

6.

Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.

Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ.

J Gastroenterol Hepatol. 2011 Sep;26(9):1380-8. doi: 10.1111/j.1440-1746.2011.06776.x.

PMID:
21884247
7.

Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.

Chen RX, Gan YH, Ge NL, Chen Y, Ma H, Wang Y, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG.

J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077.

PMID:
26259976
8.

Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.

Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK.

J Vasc Interv Radiol. 2013 Nov;24(11):1639-46. doi: 10.1016/j.jvir.2013.06.017. Epub 2013 Aug 17.

PMID:
23962438
9.

Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.

Lee S, Rhim H, Kim YS, Kang TW, Song KD.

Liver Int. 2016 Apr;36(4):580-7. doi: 10.1111/liv.12991. Epub 2015 Nov 18.

PMID:
26503910
10.

Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.

Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM.

J Gastroenterol Hepatol. 2008 Mar;23(3):467-73. Epub 2007 Aug 30.

PMID:
17764529
11.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

PMID:
28884320
12.

BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.

Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu' L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2015 Jan;35(1):223-31. doi: 10.1111/liv.12649. Epub 2014 Aug 27.

PMID:
25074434
13.

Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.

Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, Luque A, Zurera L, Espejo JJ, Rodríguez-Perálvarez M, Montero JL, de la Mata M, Briceño J.

Eur J Surg Oncol. 2015 Sep;41(9):1153-61. doi: 10.1016/j.ejso.2015.05.023. Epub 2015 Jun 12.

PMID:
26118317
14.

Management of HCC.

de Lope CR, Tremosini S, Forner A, Reig M, Bruix J.

J Hepatol. 2012;56 Suppl 1:S75-87. doi: 10.1016/S0168-8278(12)60009-9. Review.

PMID:
22300468
15.

Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study.

Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T.

J Gastroenterol Hepatol. 2008 Mar;23(3):482-90. Epub 2007 Dec 13.

PMID:
18086115
16.

Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma.

Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco).

HPB (Oxford). 2014 Aug;16(8):758-67. doi: 10.1111/hpb.12214. Epub 2014 Jan 28.

17.

HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.

Wallace MC, Huang Y, Preen DB, Garas G, Adams LA, MacQuillan G, Tibballs J, Ferguson J, Samuelson S, Jeffrey GP.

Dig Dis Sci. 2017 Aug;62(8):2182-2192. doi: 10.1007/s10620-017-4622-y. Epub 2017 May 25.

PMID:
28547649
18.

Emerging strategies for the management of hepatocellular carcinoma.

Kudo M.

Dig Dis. 2014;32(6):655-7. doi: 10.1159/000367981. Epub 2014 Oct 29. Review. No abstract available.

19.

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M.

World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545.

20.

Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.

Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C.

World J Gastroenterol. 2013 Jun 7;19(21):3207-16. doi: 10.3748/wjg.v19.i21.3207.

Supplemental Content

Support Center